clinical trial · NCT06629506
MicroMatrix® Flex in Tunneling Wounds
Pressure InjuryVenous UlcerNecrotizing Soft Tissue InfectionDiabetic UlcersDraining WoundMicroMatrix® FlexMicroMatrix® UBM ParticulateCytal® Wound Matrix 2-Layer
brief summary
To evaluate the safety and performance of MicroMatrix® Flex in subjects with wounds complicated by tunneling and/or undermining features.
started
Dec 12, 2024
primary completion
Aug 31, 2025
completion
Aug 31, 2025
last updated
Mar 5, 2026
detailed description
The purpose of this study is to evaluate the safety and performance of MicroMatrix® Flex in subjects with wounds complicated by tunneling and/or undermining features. Prospective data will be collected to assess the rate of wound area/volume reduction (progression toward closure) and post-operative complications at 12 weeks, and rate of skin graft take, when applicable, up to 16 weeks follow-up.
official title
Prospective Evaluation of MicroMatrix® Flex in Wounds Complicated by Tunneling and Undermining
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol